In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains

Yonsei Medical Journal

Volumn 51, Issue 1, 2010, Pages 111-116

  Dundar, Devrim ^a   Otkun, Metin ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

Antimicrobial; Combination; Pseudomonas aeruginosa; Synergy

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; ISEPAMYCIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CHECKERBOARD TECHNIQUE; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS; TECHNIQUE;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 75749107905     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.1.111     Document Type: Article

References (34)

1. Pier GB, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Bennet JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Volume 2. 6 th edition. Philadelphia: Churchill Livingstone; 2005. p.2587-615.
2. Clinical and laboratory standards institute. Performance standards for antimicrobial disk susceptibility tests. CLSI Document M2-A9 9th edition. Wayne, PA, USA: CLSI; 2006.
3. Clinical and laboratory standards institute: Performance standards for antimicrobial susceptibility testing. CLSI Document M100-S16 16th edition. Wayne, PA, USA: CLSI; 2006.
4. Barry AL, Thornsberry C, Jones RN, Gerlach EH. Interpretive standards for disk susceptibility tests with Sch21420 and amikacin. Antimicrob Agent Chemother 1980;18:616-21.
5. Clinical and laboratory standards institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI Document M7A6 6th edition. Wayne, PA, USA: CLSI; 2003.
6. Moody JA, Knapp C. Tests to assess bactericidal acivity. In: Isenber HD, editor. Clincal microbiology procedures handbook. Volume 2. 2nd edition. Washington: ASM Press; 2004. p.5.10.1.1-5.10.1.17.
7. Moody J. Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. In: Isenber HD, editor. Clincal microbiology procedures handbook. Volume 2. 2nd edition. Washington: ASM Press; 2004. p.5.12.1-5.12.23.
8. Eliopoulos GM, Moellering RC JR. Antimicrobial Combinations. In: Lorian V, editor. Antibiotics in Laboratory Medicine. 4 th edition. Baltimore: Williams & Wilkins; 1996. p.330-96.
9. Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. Diagn Microbiol Infect Dis 2003;47:547-50.
10. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986;80:126-37.
11. Weiss K, Lapointe JR. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agent Chemother 1995;39:2411-4.
12. Owens RC JR, Banevicius MA, Nicolau DP, Nightingale CH, Quintillani R. In vitro synergistic activities of tobramycine and selected beta-lactams against 75 gram-negative clinical isolates. Antimicrob Agent Chemother 1997;41:2586-8.
13. Chan EL, Zabransky RJ. Determination of synergy by two methods with eight antimicrobial combinations against tobramycinsusceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis 1987;6:157-64.
14. Baltch AL, Bassey C, Hammer MC, Smith RP, Conroy JV, Michelsen PB. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother 1991;27:801-8.
15. Perea EJ, Nogales MC, Aznar J, Martin E, Iglesias MC. Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa. J Antimicrob Chemother 1980;6:471-7.
16. Oie S, Sawa A, Kamiya A, Mizuno H. In vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1999;44:689-91.
17. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1997;29:81-6.
18. Clark RB, Pakiz CB, Hostetter MK. Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram. Med Microbiol Immunol 1990;179:77-86.
19. Gerçeker AA, Gürler B. In vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother 1995;36:707-11.
20. Bustamante CI, Drusano GL, Wharton RC, Wade JC. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agent Chemother 1987;31:632-4.
21. Gould IM, Milne K. In vitro pharmacodynamic studies of piperacillin/ tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother 1997;39:53-61.
22. Laverdière M, Gallimore B, Restieri C, Poonia K, Chow AW. In vitro synergism of ceftriaxone combined with aminoglicosides against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1994;19:39-46.
23. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997;41:95-100.
24. Jones RN, Johnson DM, Barrett MS, Erwin ME. Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. J Chemother 1991;3:289-94.
25. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of betalactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginsa. Int J Antimicrob Agents 2003;1:8-12.
26. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin and travofloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis 2000;38:37-41.
27. Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin and travafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. Diagn Microbiol Infect Dis 1999;33:81-6.
28. Neu HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis 1991;10:255-61.
29. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002;50:1045-9.
30. Drago L, De Vechi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy 2004;50:202-10.
31. Mayer I, Nagy E. Investigation of the synergic effects of amino-glycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 1999;43:651-7.
32. Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Bennet JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Volume 1. 6 th edition. Philadelphia: Churchill Livingstone; 2005. p.294-311.
33. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennet JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Volume 1. 6 th edition. Philadelphia: Churchill Livingstone; 2005. p.328-56.
34. Perry CM, Markham A. Piperasillin/tazobactam an updated review of its use in the treatment of bacterial infections. Drugs 1999;57:805-43.